Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Hemminki

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Oncoimmunology|April 9, 2016
A century of oncolysis evolves into oncolytic immunotherapyO Hemminki, A Hemminki
Gene Therapy|November 11, 2011
Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4J D Dias, O Hemminki, I Diaconu, et al.
Cancer Gene Therapy|December 25, 2010
Oncolytic adenovirus based on serotype 3O Hemminki, G Bauerschmitz, S Hemmi, et al.
International Journal of Cancer|November 20, 2013
In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus respondersO Hemminki, R Immonen, J Närväinen, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Oncoimmunology|April 9, 2016
A century of oncolysis evolves into oncolytic immunotherapyO Hemminki, A Hemminki
Gene Therapy|November 11, 2011
Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4J D Dias, O Hemminki, I Diaconu, et al.
Cancer Gene Therapy|December 25, 2010
Oncolytic adenovirus based on serotype 3O Hemminki, G Bauerschmitz, S Hemmi, et al.
International Journal of Cancer|November 20, 2013
In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus respondersO Hemminki, R Immonen, J Närväinen, et al.
Pageof 1